SAN DIEGO --(BUSINESS WIRE)--Oct. 8, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2020 results after the financial markets close on Thursday, November 5, 2020 .
SAN DIEGO --(BUSINESS WIRE)--Sep. 2, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan , president and chief executive officer, will present a company update at the following virtual investor conferences:
SAN DIEGO --(BUSINESS WIRE)--Aug. 27, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by the New England Journal of Medicine (NEJM) of results from the Protocol 5 study (DCLP5) of the International Diabetes
SAN DIEGO --(BUSINESS WIRE)--Jul. 30, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2020 . In addition, the Company provided sales guidance for the year ending
SAN DIEGO --(BUSINESS WIRE)--Jul. 29, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Peyton Howell as an independent member of its board of directors effective August 3, 2020 . Ms.
DUBLIN & SAN DIEGO --(BUSINESS WIRE)--Jul. 9, 2020-- Medtronic plc (NYSE:MDT) and Tandem Diabetes Care, Inc. (NASDAQ:TNDM) today announced that they have entered into a non-exclusive patent cross-license agreement for certain technologies in the field of diabetes.
SAN DIEGO --(BUSINESS WIRE)--Jul. 8, 2020-- JDRF, the leading global organization funding type 1 diabetes (T1D) research, and Tandem Diabetes Care (NASDAQ: TNDM), a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary
SAN DIEGO --(BUSINESS WIRE)--Jul. 7, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2020 results after the financial markets close on Thursday, July 30, 2020 .
- Companies partner to integrate Abbott's FreeStyle Libre continuous glucose monitoring technology with Tandem's insulin delivery products to provide options to simplify and tailor diabetes management ABBOTT PARK, Ill. and SAN DIEGO , June 29, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) and Tandem
SAN DIEGO --(BUSINESS WIRE)--Jun. 24, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced its acquisition of Sugarmate, a popular mobile app for people with diabetes who use insulin.
SAN DIEGO --(BUSINESS WIRE)--Jun. 17, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of an expanded pediatric indication for the t:slim X2™ insulin pump with Control-IQ™
SAN DIEGO --(BUSINESS WIRE)--Jun. 13, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today presented positive real-world data from early use of the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed loop technology,
SAN DIEGO --(BUSINESS WIRE)--Jun. 4, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Kathleen McGroddy-Goetz , Ph.D., as an independent member of its Board of Directors effective June 8, 2020 . Dr.
SAN DIEGO --(BUSINESS WIRE)--May 29, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan , president and chief executive officer, will present a company update at the following virtual investor conferences:
SAN DIEGO --(BUSINESS WIRE)--May 18, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that its 2020 Annual Meeting of Stockholders (“Annual Meeting”) will be held in a virtual-only format due to continued public health
SAN DIEGO --(BUSINESS WIRE)--May 13, 2020-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) (“Tandem” or, the “Company”) announced today the pricing of $250.0 million aggregate principal amount of 1.50 percent Convertible Senior Notes due 2025 (the “Notes”) in a private placement to persons reasonably
SAN DIEGO --(BUSINESS WIRE)--May 12, 2020-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM) (“Tandem” or, the “Company”) announced today that it intends to offer, subject to market conditions and other factors, $250.0 million aggregate principal amount of Convertible Senior Notes due 2025 (the “Notes”)
SAN DIEGO --(BUSINESS WIRE)--May 7, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan , president and chief executive officer, will present a company update at the following virtual investor conferences:
Second Quarter 2020 Sales Guidance Provided, Annual Guidance Withdrawn SAN DIEGO --(BUSINESS WIRE)--Apr. 30, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2020 .
SAN DIEGO --(BUSINESS WIRE)--Apr. 9, 2020-- Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2020 results after the financial markets close on Thursday, April 30, 2020 .
